Use my Search Websuite to scan PubMed, PMCentral, Journal Hosts and Journal Archives, FullText. Kick-your-searchterm to multiple Engines kick-your-query now !>

A dictionary by aggregated review articles of nephrology, medicine and the life sciences Your one-stop-run pathway from word to the immediate pdf of peer-reviewed on-topic knowledge.

10.1177/2472555220963667 http://scihub22266oqcxt.onion/10.1177/2472555220963667 33043784!7550789!33043784     free     free     free Deprecated: Implicit conversion from float 233.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 233.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 233.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 233.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534       SLAS+Discov 2020 ; 25 (10): 1152-1161 Nephropedia Template TP {{tp|p=33043784|t=2020. High-Throughput Screening for Drugs That Inhibit Papain-Like Protease in SARS-CoV-2 |pdf=|usr=}}{{33043784}} gab.com Text High-Throughput Screening for Drugs That Inhibit Papain-Like Protease in SARS-CoV-2 JO: SLAS Discov http://www.kidney.de/pget.php?&tw=1&pmid=33043784 #FOAvip The emergence of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in late 2019 has triggered an ongoing global pandemic whereby infection may result in a lethal severe pneumonia-like disease designated as coronavirus disease 2019 (COVID-19). To date, millions of confirmed cases and hundreds of thousands of deaths have been reported worldwide, and there are currently no medical countermeasures available to prevent or treat the disease. The purported development of a vaccine could require at least 1-4 years, while the typical timeline from hit finding to drug registration of an antiviral is >10 years. Thus, repositioning of known drugs can significantly accelerate the development and deployment of therapies for COVID-19. To identify therapeutics that can be repurposed as SARS-CoV-2 antivirals, we developed and initiated a high-throughput cell-based screen that incorporates the essential viral papain-like protease (PLpro) and its peptide cleavage site into a luciferase complementation assay to evaluate the efficacy of known drugs encompassing approximately 15,000 clinical-stage or US Food and Drug Administration (FDA)-approved small molecules. Confirmed inhibitors were also tested to determine their cytotoxic properties. Here, we report the identification of four clinically relevant drugs that exhibit selective inhibition of the SARS-CoV-2 viral PLpro. Twit Text FOAVip High-Throughput Screening for Drugs That Inhibit Papain-Like Protease in SARS-CoV-2 ????SLAS Discov http://www.kidney.de/pget.php?&tw=1&pmid=33043784 #FOAvip Twit Text # Free Paper on # # # # # LINK http://www.kidney.de/pget.php?&tw=1&pmid=33043784 #FOAvip English Wikipedia <ref>{{Cite pmid|33043784}}</ref> High-Throughput Screening for Drugs That Inhibit Papain-Like Protease in SARS-CoV-2 #MMPMID33043784 Smith E; Davis-Gardner ME; Garcia-Ordonez RD; Nguyen TT; Hull M; Chen E; Baillargeon P; Scampavia L; Strutzenberg T; Griffin PR; Farzan M; Spicer TP SLAS Discov 2020[Dec]; 25 (10): 1152-1161 PMID33043784show ga The emergence of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in late 2019 has triggered an ongoing global pandemic whereby infection may result in a lethal severe pneumonia-like disease designated as coronavirus disease 2019 (COVID-19). To date, millions of confirmed cases and hundreds of thousands of deaths have been reported worldwide, and there are currently no medical countermeasures available to prevent or treat the disease. The purported development of a vaccine could require at least 1-4 years, while the typical timeline from hit finding to drug registration of an antiviral is >10 years. Thus, repositioning of known drugs can significantly accelerate the development and deployment of therapies for COVID-19. To identify therapeutics that can be repurposed as SARS-CoV-2 antivirals, we developed and initiated a high-throughput cell-based screen that incorporates the essential viral papain-like protease (PLpro) and its peptide cleavage site into a luciferase complementation assay to evaluate the efficacy of known drugs encompassing approximately 15,000 clinical-stage or US Food and Drug Administration (FDA)-approved small molecules. Confirmed inhibitors were also tested to determine their cytotoxic properties. Here, we report the identification of four clinically relevant drugs that exhibit selective inhibition of the SARS-CoV-2 viral PLpro. |Antiviral Agents/*pharmacology[MESH] |Bleomycin/pharmacology[MESH] |COVID-19 Drug Treatment[MESH] |Coronavirus 3C Proteases/*antagonists & inhibitors/genetics/metabolism[MESH] |HEK293 Cells[MESH] |High-Throughput Screening Assays/*methods[MESH] |Humans[MESH] |Papain/chemistry[MESH] |Protease Inhibitors/*pharmacology[MESH]High-Throughput Screening for Drugs That Inhibit Papain-Like Protease (epmc).pdf DeepDyve Pubget Overpricing